Harrow Health, Inc., together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the United States. The company offers ophthalmology based pharmaceutical products; and operates Visionology, an online eye health and medication platform. It also develops and commercializes therapeutics for treating ocular surface diseases; and non-intravenous sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. Its products portfolio includes SURF-201 that is in phase 2 trial for the treatment of post cataract surgery pain and inflammation; SURF-100, which is in phase 2 trial to treat chronic dry eye disease; SURF-200 that is in phase 2 trial for the treatment of episodic dry eye flares; and MELT-100, a drug candidate, which has completed Phase I clinical trial for procedural sedation. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.